Results 21 to 30 of about 279,445 (313)

Alveolar cells under mechanical stressed niche: critical contributors to pulmonary fibrosis

open access: yesMolecular Medicine, 2020
Pulmonary fibrosis arises from the repeated epithelial mild injuries and insufficient repair lead to over activation of fibroblasts and excessive deposition of extracellular matrix, which result in a mechanical stretched niche.
Juntang Yang   +3 more
doaj   +1 more source

Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events [PDF]

open access: yes, 2014
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival.
Per M. Hellström   +46 more
core   +1 more source

[Idiopathic pulmonary fibrosis].

open access: yesMedecine sciences : M/S, 2022
38;6 ...
Hennion, Nathan   +4 more
openaire   +6 more sources

Informal caregivers experience of supplemental oxygen in pulmonary fibrosis

open access: yesHealth and Quality of Life Outcomes, 2017
Background Patients prescribed supplemental oxygen (O2) therapy face challenges as they adjust to being constantly “tethered” to an oxygen delivery device.
Bridget A. Graney   +8 more
doaj   +1 more source

Obstructive sleep apnea and nocturnal hypoxemia in adult patients with cystic fibrosis

open access: yesBMC Pulmonary Medicine, 2022
Background Obstructive sleep apnea (OSA), nocturnal hypoxemia and excessive daytime sleepiness (EDS) are common comorbidities in people with cystic fibrosis (pwCF). Most of the data showing this originates from children and adolescents.
Matthias Welsner   +10 more
doaj   +1 more source

Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome. [PDF]

open access: yes, 2012
The state of oligomerization of surfactant associated protein-A (SP-A) monomers differs between individuals. This likely affects SP-A's functional properties and could thereby influence clinical status in patients with lung diseases.
Karl Paul   +15 more
core   +1 more source

Pulmonary rehabilitation in idiopathic pulmonary fibrosis and COPD: a propensity matched real-world study [PDF]

open access: yes, 2021
BACKGROUND: The adherence to and clinical efficacy of pulmonary rehabilitation in idiopathic pulmonary fibrosis (IPF), particularly in comparison to people with chronic obstructive pulmonary disease (COPD), remains uncertain.
Ingram, Karen A   +21 more
core   +1 more source

Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum [PDF]

open access: yes, 2009
Background Prior microrheologic assessments of selected, microlitre plugs of cystic fibrosis (CF) sputum suggest no intrinsic rheologic abnormality. However, such analyses may not be representative of CF sputum as a whole.
Young Simon A   +7 more
core   +1 more source

Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis [PDF]

open access: yes, 2021
Fibrotic Interstitial lung diseases (ILDs) are complex disorders of variable clinical behaviour. The majority of them cause significant morbidity, whilst Idiopathic Pulmonary Fibrosis (IPF) is recognised as the most relentless.
Mastrodimou, Semeli   +9 more
core   +1 more source

Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report

open access: yesBMC Pulmonary Medicine, 2019
Background CFTR modulator therapy with ivacaftor is a treatment option for Cystic Fibrosis (CF) patients with at least one copy of a R117H-7T mutation in the CFTR gene.
Matthias Welsner   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy